ArticleRedox biology2026
Allosteric activation of Trx1 by antagonizing nitrative modification at tyrosine 49 confers neuroprotection against ischemic stroke.
Article in Redox biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ischemic stroke remains a leading cause of mortality and chronic disability worldwide, with limited therapeutic options. Tetramethylpyrazine (TMP) is a natural product with well-established clinical efficacy against ischemic stroke, yet its molecular target and mechanism of action remain elusive. By integrating a bifunctional photoaffinity TMP probe with stable isotope labeling by amino acids in cell culture and activity-based protein profiling (SILAC-ABPP), we identified thioredoxin 1 (Trx1) as a direct target of TMP. We demonstrate that TMP binds specifically to tyrosine 49 (Y49) on Trx1, antagonizes its nitrative modification, and functions as an allosteric activator. This binding enhances Trx1's reductase activity, strengthens its interaction with apoptosis signal-regulating kinase 1 (ASK1), and consequently suppresses the ASK1-p38/JNK signaling cascade. Genetic ablation of Trx1 or ASK1, or pharmacological induction of Trx1 nitration, completely abolishes TMP-mediated neuroprotection. Our findings not only decipher the mechanistic basis for TMP's clinical efficacy but also identify Y49 of Trx1 as a druggable allosteric site, unveiling a novel anti-nitrative therapeutic strategy for ischemic stroke and related disorders involving nitrative stress.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.